Navigation Links
Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia,Clinical Trial

per protocol clinical cure rate compared to Biaxin(R) in CAP (cethromycin 91.5% (205/224) compared to Biaxin(R) 95.9% (212/221) [-9.1, +0.3], p=0.0775). Cethromycin's achievement of a 91.5% clinical cure rate is consistent with its Phase 2 clinical trial results at the same 300 mg once-daily dose for CAP. The comparator drug, Biaxin(R), achieved a cure rate higher than the historical rate observed in any reported Biaxin(R) CAP clinical trials to date.

Cethromycin also achieved positive safety results in the study. Cethromycin demonstrated an improved safety profile when compared with the results seen in its previous clinical trials. Additionally, the incidence of adverse events was not statistically different between cethromycin and Biaxin(R). The most common adverse events reported in patients receiving cethromycin were mild-to-moderate diarrhea (cethromycin 5.0%, Biaxin(R) 4.6%), headache (cethromycin 3.1%, Biaxin(R) 6.5%), nausea (cethromycin 2.7%, Biaxin(R) 3.8%), vomiting (cethromycin 2.7%, Biaxin(R) 1.5%), abdominal pain (cethromycin 1.5%, Biaxin(R) 3.1%) and taste disturbance (cethromycin 11.1%, Biaxin(R) 6.2%). No drug-related serious adverse events were observed in any study subject. Liver function tests and electrocardiogram monitoring demonstrated no significant differences between subjects receiving cethromycin and subjects receiving Biaxin(R), consistent with the hepatic and cardiac side effect profile reported in cethromycin's previous clinical trials.

Cethromycin is not approved as a treatment for CAP, and data from this analysis have not been reviewed by the FDA. No further details of the clinical study will be available until all data analyses are complete and results are presented in a public, scientific forum.

Program Design

The Phase 3 CAP clinical trial program is comprised of two randomized, well controlled, double-blind, multi-center, multi-national, comparator trials designed to assess the safety and effectiveness
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
2. Cethromycin Shown Effective Against Anthrax in Study
3. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
4. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
7. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
8. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
9. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
Post Your Comments:
(Date:5/17/2013)... May 17, 2013  Boston Scientific Corporation (NYSE: ... annual EuroPCR Scientific Program May 21-24 in ... present a particularly rich and diversified set of data ... , M.D., global chief medical officer, Boston Scientific.  ... presented, including the NG PROMUS trial, which evaluated our ...
(Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
(Date:5/16/2013)... SYDNEY , May 16, 2013  HeartWare International, Inc. ... innovator of less invasive, miniaturized circulatory support technologies that are ... CEO Doug Godshall is scheduled to ... a.m. EDT on Monday, May 20, 2013.  The conference is ... Hotel. A live webcast of the Company,s presentation ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
... U.S. Food and Drug Administration today approved Eylea (aflibercept) ... (AMD), a leading cause of vision loss and blindness ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) AMD gradually destroys a ... part of the eye that allows people to see ...
...  Merrimack Pharmaceuticals, Inc. announced today that the first patient ... of MM-121, a fully human monoclonal antibody that targets ... directed at the epidermal growth factor receptor (EGFR), in ... cancer (NSCLC).  (Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO ...
Cached Medicine Technology:FDA Approves Eylea for Eye Disorder in Older People 2Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer 2
(Date:5/19/2013)... Fat Burning Furnace developed by Rob Poulos is ... fat burning diet plans, training workouts, and ... package, people will receive the Fat Burning Furnace manual, ... Fat Burning Furnace manual includes fat loss knowledge, and ... In addition, this book covers step-by-step instructions, techniques and ...
(Date:5/19/2013)... Americans live closer to their dogs than ever ... Association (AVMA) U.S. Pet Ownership and Demographics Sourcebook, more ... a member of the family, up from the 53.5% ... earlier. , According to the American Pet Products Association, ... to pets has increased every year without interruption, including ...
(Date:5/19/2013)... Dr. Keith Chertok now provides gum disease patients ... and increase the chance of a healthier smile. Laser ... (LANAP) not only removes diseased gum tissue in patients, but ... for dental implants. , LANAP uses a laser ... also help stimulate the healthy tissue as well as encourage ...
(Date:5/19/2013)... May 19, 2013 Vegas Hotel Escapes, ... proud to announce the launch it's all new vacation ... MGM Grand on 5/19/2013. Consumers traveling to Las Vegas ... pricing available on VegasHotelEscapes.com's website. Travelers will be pleased ... any competitors price. , Vegas Hotel Escapes specializes in ...
(Date:5/19/2013)... Agora Health Limited developed by Rachael Linkie is ... how to increase memory power naturally and effectively. The ... people re-new their entire health from the inside out. It ... a fatigued mind. In addition, the program helps people keep ... The author claimed that this program can help people overcome ...
Breaking Medicine News(10 mins):Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2
... bikers, brains, may also be contributing to hearing loss. ... out why. The distinctive roar of a Harley,s ... source of noise for motorcyclists is actually generated by ... speeds, the sound can exceed safe levels. Now, scientists ...
... at Washington University School of Medicine in St. Louis ... National Cancer Institute (NCI) to study the relationship between ... the Transdisciplinary Research on Energetics and Cancer (TREC) Center. ... weight, physical activity and the environment on cancer and ...
... Some compounds found in grapes help to protect skin ... study by researchers from the University of Barcelona and ... the use of grapes or grape derivatives in sun ... sun are the leading environmental cause of skin complaints, ...
... 29, 2011More than eight in 10 Ontarians say they would ... they were seriously injured, even if another hospital were closer, ... researchers at St. Michael,s Hospital, also found that 40 per ... trauma centre within an hour of calling 911. Neither ...
... A sudden drop in blood pressure while undergoing dialysis has ... situation over the long term range from stroke to seizure ... short term with gastrointestinal, muscular and neurologic symptoms. Now ... this list. A study led by researchers at the ...
... ripples and fast ripples, recorded by intracranial electroencephalography ... localization of the brain region responsible for seizure ... Epilepsia , a journal of the International ... regions containing fast ripples, along with the visually-identified ...
Cached Medicine News:Health News:WU studies obesity, cancer link with $9.2 million grant 2Health News:Grapes protect against ultraviolet radiation 2Health News:Survey: Ontarians expect better access to trauma centers for serious injuries 2Health News:Survey: Ontarians expect better access to trauma centers for serious injuries 3Health News:Low blood pressure during dialysis increases risk of clots, according to Stanford-led study 2Health News:Fast ripples confirmed to be valuable biomarker of area responsible for seizure activity in children 2
... The RCAI Bariatric Knee Immobilizer is ... lateral stays with a breathable foam material ... , ,The posterior aspect of the ... custom anatomical fit. The loop and lock ...
... breathable foam. Three piece design for precise ... loop closures. Lightweight rigid posterior stays with ... with optional hot and cold therapy Gel ... pain cycle by providing cold therapy to ...
... Neuroprene™ soft supports are a ... to proprioceptive taping for common orthopedic ... help provide specific compression and lateral ... receptors (proprioceptors) in the skin and ...
... UltraWrap™ is a low-profile, wraparound, hinged ... Ideal for patients who have difficulty ... contouring pull points for ease of application. ... correctly fit and easily secure the anterior ...
Medicine Products: